Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 16, 2018 4:28:12 AM
Your tidbit uses term 'average' instead of median for durations. That would be the first. So far all other reported measures comparing OM durations have been using medians, which is, in my opinion, very misleading when the duration distributions are fat tailed as they tend to be with OM.
But, if GALERA is reporting real averages then...
The reduction reported would be immense if it is FROM AVERAGE of 19 days with placebo to AVERAGE of 1.5 days with GC4419.
But there might be a problem brewing...
I can't find the word average in any other report about GALERA's trial results.
Galera's site is currently inaccessible but Google cache shows no word average in the item on Galera's own site. See this:
"Phase 2b clinical trial demonstrate GC4419’s ability to dramatically reduce the duration of severe OM from 19 days to 1.5 days (92 percent)"
and the same in here.
It looks like your quote is the ONLY one using the word average as if the writer had decided to add some color into otherwise dry report.
Let's see how this will go:
If GALERA is REALLY reporting real changes in real averages then Leo has reasons to be worried, not desperate, but worried.
If the reported values turn out to be medians then it is the same old garbage, and not that much better garbage than what was reported for Kepivance
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM